Literature DB >> 6941454

Action of clinically utilized 5-nitroimidazoles on microorganisms.

M Müller.   

Abstract

Various nitroimidazoles are used as antimicrobial and radiosensitizing agents in human medicine. Of these, 5-nitroimidazoles show high selective toxicity for anaerobic prokaryotes and eukaryotes. This review discusses the effects of 5-nitroimidazoles on microorganisms, i.e. microbicidal action, radiosensitizing action, inhibition of photosynthetic microorganisms, and induction of mutations. All these actions are enhanced by anaerobiosis and inhibited by aerobiosis or by the presence of certain reducible compounds. There is no indication that antimicrobial action could be dissociated from mutagenic properties. Relative resistance to 5-nitroimidazoles has been detected in some isolates of Bacteroides fragilis and Trichomonas vaginalis and was experimentally developed in B. fragilis and various trichomonads. Nitroimidazoles enter the microorganisms by diffusion. Facilitated transport has not been detected. The compound is reduced by low oxidation-reduction potential ferredoxin and similar electron transport components in the cell. In microorganisms highly susceptible to metronidazole, such compounds play a significant metabolic role. The reduction increases the outside-inside concentration gradient and thus drives further uptake. Certain short-lived products of the reduction are responsible for the cytotoxic action. In less susceptible organisms only limited amounts of such products are formed, and thus the cells are not killed but may undergo mutations. A major component of cytotoxicity is damage to DNA but other mechanisms cannot be excluded at present.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6941454

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  11 in total

1.  Impact on peritonsillar infections and microflora of phenoxymethylpenicillin alone versus phenoxymethylpenicillin in combination with metronidazole.

Authors:  K Tunér; C E Nord
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

2.  Impact of topical metronidazole on the skin and colon microflora in patients with rosacea.

Authors:  G Eriksson; C E Nord
Journal:  Infection       Date:  1987 Jan-Feb       Impact factor: 3.553

3.  Interaction of metronidazole with DNA repair mutants of Escherichia coli.

Authors:  T C Yeung; B B Beaulieu; M A McLafferty; P Goldman
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 4.  Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis.

Authors:  J C Gillis; L R Wiseman
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

5.  Metabolism and metronidazole uptake in Trichomonas vaginalis isolates with different metronidazole susceptibilities.

Authors:  M Müller; T E Gorrell
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 6.  Tinidazole in anaerobic infections: a review of its antibacterial activity, pharmacological properties and therapeutic efficacy.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-08       Impact factor: 9.546

7.  Pyruvate decarboxylase, the target for omeprazole in metronidazole-resistant and iron-restricted Tritrichomonas foetus.

Authors:  Róbert Sutak; Jan Tachezy; Jaroslav Kulda; Ivan Hrdý
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 8.  Gardnerella vaginalis: characteristics, clinical considerations, and controversies.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

Review 9.  Tinidazole--microbiology, pharmacology and efficacy in anaerobic infections.

Authors:  C E Nord; L Kager
Journal:  Infection       Date:  1983 Jan-Feb       Impact factor: 3.553

Review 10.  Metronidazole vaginal gel 0.75% (MetroGel-Vaginal): a brief review.

Authors:  A M Wain
Journal:  Infect Dis Obstet Gynecol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.